|
Registro Completo |
|
Biblioteca(s): |
Embrapa Pecuária Sul. |
|
Data corrente: |
21/12/2022 |
|
Data da última atualização: |
21/12/2022 |
|
Tipo da produção científica: |
Capítulo em Livro Técnico-Científico |
|
Autoria: |
PORTILHO, A. I.; CORREA, V. A.; GASPAR, E. B.; DE GASPARI, E. |
|
Afiliação: |
AMANDA IZELI PORTILHO, Instituto Adolfo Lutz; VICTOR ARAUJO CORREA, Instituto Adolfo Lutz; EMANUELLE BALDO GASPAR, CPPSUL; ELIZABETH DE GASPARI, Instituto Adolfo Lutz. |
|
Título: |
Different platforms, immune response modulators and challenges in SARS-COV-2 vaccination. |
|
Ano de publicação: |
2022 |
|
Fonte/Imprenta: |
Zurich: Springer, 2022. |
|
Páginas: |
p. 539-559. |
|
DOI: |
10.1007/978-3-031-08045-6_26 |
|
Idioma: |
Inglês |
|
Conteúdo: |
Vaccination is one of the most powerful measures to control infectious diseases. Nowadays, technical advances allowed the recognition of key aspects of pathogen?host interaction and the spread of such information, which was applied in vaccine development. The urge to control the COVID-19 pandemic resulted in vaccines development in record time, approximately 1 year after the emergence of SARS-CoV-2. The use of classic and innovative vaccine platforms and adjuvants was employed at several locations, by different groups. Here, we discuss how the pandemic scenario influences vaccine development, the implications of the route of immunization and adjuvant choice for vaccines, and the need to consider all these aspects in relation to the current scenario, also preparing ourselves to future pandemics. |
|
Thesagro: |
Imunidade; Imunização; Vacina; Vírus. |
|
Categoria do assunto: |
H Saúde e Patologia |
|
Marc: |
LEADER 01436naa a2200229 a 4500
001 2150164
005 2022-12-21
008 2022 bl uuuu u00u1 u #d
024 7 $a10.1007/978-3-031-08045-6_26$2DOI
100 1 $aPORTILHO, A. I.
245 $aDifferent platforms, immune response modulators and challenges in SARS-COV-2 vaccination.$h[electronic resource]
260 $c2022
300 $ap. 539-559.
520 $aVaccination is one of the most powerful measures to control infectious diseases. Nowadays, technical advances allowed the recognition of key aspects of pathogen?host interaction and the spread of such information, which was applied in vaccine development. The urge to control the COVID-19 pandemic resulted in vaccines development in record time, approximately 1 year after the emergence of SARS-CoV-2. The use of classic and innovative vaccine platforms and adjuvants was employed at several locations, by different groups. Here, we discuss how the pandemic scenario influences vaccine development, the implications of the route of immunization and adjuvant choice for vaccines, and the need to consider all these aspects in relation to the current scenario, also preparing ourselves to future pandemics.
650 $aImunidade
650 $aImunização
650 $aVacina
650 $aVírus
700 1 $aCORREA, V. A.
700 1 $aGASPAR, E. B.
700 1 $aDE GASPARI, E.
773 $tZurich: Springer, 2022.
Download
Esconder MarcMostrar Marc Completo |
|
Registro original: |
Embrapa Pecuária Sul (CPPSUL) |
|
